As the FEd nears end of raising interest rates , look for rotation into technology,healthcare,food, and biotech sectors.Gold and oils will be in trading range. Favorite pick in tech is OBJ. Food and beverage pick is FGL. Healthare pick is Mayne. In the biotech sector PTD is solid with royalty income for next few years from the Humira and Embrel drugs. Biota has good upside potential especially if wins trial but it has doubled from recent 73 cents price and is now in trading range. Best upside pick in Biotech arena could be Sirtex medical which 2 years ago received $4.85 bid from Cephalon which was rejected. Sirtex is at $1.95 now and selling at only 39% of previous buyout offer. IT has made tremendous progress since it rejected bid and is becoming entrenched in over 60 US hospitals in administering Sir Spheres at $14,000 USD per treatment and revenues are taking off up 130 % with similar profit growth. THis is due to its use with new chemotherpy drugs from Pfizer and Sanofi. AT $2 upside is about 3.80 short term based on fibinacci chart into next report a month away.Hunter Hall owns 22 % of the co and says in a buyout it is worth about 7-9 dollars as revenue growth continues.
